Presentations

VALOR, an adaptive design, pivotal phase III trial of vosaroxin or placebo in combination with cytarabine in first relapsed or refractory acute myeloid leukemia.

Adaptive Design of VALOR, a Phase 3 Trial of Vosaroxin or Placebo in Combination with Cytarabine for Patients With First Relapsed or Refractory Acute Myeloid Leukemia.

Vosaroxin in AML.

Results of a phase 2 pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Results from a phase 2 study with three schedules.

Final results of a phase 2 study of voreloxin in women with platinum-resistant ovarian cancer.

Phase 1b/2 Pharmacokinetic/Pharmacodynamic Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory AML Patients.

A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.

Clinical Evidence of Mechanism-Based Pharmacodynamic Activity in Voreloxin-Treated AML Patients.

Voreloxin is Synergistic in In Vitro Combination with Cytarabine and Additive in Combination with Azacitidine, Decitabine and Clofarabine.

Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients.

A phase II trial of voreloxin in women with platinum-resistant ovarian cancer.

A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML).

Voreloxin is active in breast cancer biopsies and potency is enhanced in a BRCA2 mutant background

Voreloxin as a Topoisomerase II Poison: Role of DNA Intercalation

Phase 2 Study of Voreloxin (SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses

Voreloxin in Combination with Cytarabine Demonstrates Preliminary Clinical Responses in a Phase 1b/2 Study In Relapsed/Refractory Acute Myeloid Leukemia

Voreloxin (SNS-595) in Platinum-Resistant Ovarian Cancer

Voreloxin (SNS-595): An Active Agent in AML

A Phase 2 Trial of Voreloxin (formerly SNS-595) in Women with Platinum-Resistant Ovarian Cancer

Voreloxin (formerly SNS-595) is a potent DNA intercalator and topoisomerase II poison that induces cell cycle dependent DNA damage and rapid apoptosis in cancer cell lines

Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients ≥60 years old Compared to < 60 years old: Results of a Phase 1b Study

A Phase 2 Trial of Voreloxin (Formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian Cancer

Ex Vivo Activity of SNS-595 Against Biopsies of Acute Myeloid Leukemia, Triple Negative Breast and Ovarian Cancers Supports Ongoing and Potential Clinical Indications

Sensitivity to SNS-595 is Related to Activation of Double Strand DNA Break Repair Pathways Including Homologous Recombination

SNS-595 is a potent anti-tumor agent that has a dual mechanism of action: DNA intercalation and site-selective topoisomerase II poisoning

SNS-595: A cancer therapeutic and novel DNA damaging agent

A Phase 2 Trial of SNS-595 in Women with Platinum Resistant Epithelial Ovarian Cancer

A Phase 1b Open-Label Study of the Novel DNA Replication Inhibitor SNS-595 in Refractory Acute Leukemia

SNS-595 demonstrates predictable, dose-proportional pharmacokinetics in three Phase 1 clinical studies

SNS-595 potentiates the in vivo anti-tumor activity of carboplatin, cisplatin, and gemcitabine in solid tumor xenografts

A Phase 2 Trial of SNS-595 in Women with Platinum Resistant Epithelial Ovarian Cancer

SNS-595: Preliminary Results Of Two Phase 2 Second Line Studies In Lung Cancer

Pharmacokinetic/Pharmacodynamic Correlation with Clinical Responses in a Phase 1 Study of Patients with Relapsed/Refractory Acute Leukemias Treated with SNS 595

A Phase 1 Dose-Escalation Study of the Novel Cell Cycle Active Agent SNS-595 in Advanced Leukemias

SNS-595 A Novel S-Phase Active Cytotoxic Acts Synergistically With Cytarabine To Reduce Bone Marrow Cellularity And Circulating Neutrophils

SNS-595 demonstrates Clinical Activity and Dose Proportional Pharmacokinetics (PK) in Two Phase 1 Clinical Studies

SNS-595 Has Synergistic Activity In Vitro With DNA Damaging Agents And Antimetabolites

SNS-595, A Novel S-Phase Active Cytotoxic, Exhibits Potent In Vitro And In Vivo Activities, And Has The Potential For Treating Advanced Hematologic Malignancies

A Phase 1 Trial Of Weekly SNS-595 In Patients (PTS) With Refractory Cancer

CYP450 Inhibition, Induction, Metabolism and Routes of Elimination of SNS-595, a Novel Cell Cycle Inhibitor Currently in Phase I Clinical Trials

Results of a Phase I Trial of SNS-595 in Patients with Advanced Solid Malignancies

SNS-595, A Novel Cell Cycle Inhibitor in Phase 1 Clinical Trials, Causes Tumor Regressions, Cell-Cycle Arrest, and Apoptosis in Murine Models of Cancer

The Phase 1 Clinical Compound SNS-595 Acts During S-Phase and Causes a Sustained G2 Arrest

The potent cytotoxic agent SNS-595 causes a rapid onset of apoptosis during the S-phase of the cell cycle

ADMET and pharmacokinetic properties of SPC-595, a novel cell cycle inhibitory antineoplastic agent in non-clinical species

Non-clinical admet, pk, and biological activity of SNS-595, a novel cell cycle inhibitory antineoplastic agent

In vitro and in vivo activity of SPC-595, a novel cell cycle inhibitory cytotoxic in murine syngeneic and human xenograft tumor models

BIIB024, a potent pan-Raf kinase inhibitor for melanoma and solid tumors